Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Sakajiri

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Ryoikibetsu Shokogun Shirizu|March 28, 2001
[Autoimmune myelodysplasias]S Sakajiri, K Oshimi
Japanese Journal of Cancer Research : Gann|October 26, 2001
Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasmsS Sakajiri, N Kawamata, M Egashira, et al.
Oncogene|November 17, 2005
DLK1: increased expression in gliomas and associated with oncogenic activitiesD Yin, D Xie, S Sakajiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapyD Ennishi, M Yokoyama, Y Terui, et al.
Leukemia|June 17, 2005
Dlk1 in normal and abnormal hematopoiesisS Sakajiri, J O'kelly, D Yin, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Ryoikibetsu Shokogun Shirizu|March 28, 2001
[Autoimmune myelodysplasias]S Sakajiri, K Oshimi
Japanese Journal of Cancer Research : Gann|October 26, 2001
Molecular analysis of tumor suppressor genes, Rb, p53, p16INK4A, p15INK4B and p14ARF in natural killer cell neoplasmsS Sakajiri, N Kawamata, M Egashira, et al.
Oncogene|November 17, 2005
DLK1: increased expression in gliomas and associated with oncogenic activitiesD Yin, D Xie, S Sakajiri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapyD Ennishi, M Yokoyama, Y Terui, et al.
Leukemia|June 17, 2005
Dlk1 in normal and abnormal hematopoiesisS Sakajiri, J O'kelly, D Yin, et al.
Pageof 1